Killing cancer cells by flipping the Bcl-2/Bax switch
- Details
- Publication Year 2005-07,Volume 8,Issue #1,Page 5-6
- Journal Title
- CANCER CELL
- Publication Type
- Journal Article
- Abstract
- impairment of apoptosis, the physiologic cell death process, is central to cancer development and renders tumors refractory to cytotoxic therapy. Bcl-2, the oncoprotein activated in follicular lymphoma, inhibits the conserved cell death pathway triggered by diverse cytotoxic agents, as do several close relatives. A small-molecule antagonist of these proteins has now been designed by Oltersdorf et al. Strikingly, ABT 737 sensitizes many tumors to cytotoxic agents and is effective as a single agent against certain lymphomas and solid tumors, provoking stable regression in some tumor xenografts. Hence, this work validates Bcl-2-like proteins as important new targets in cancer therapy.
- Publisher
- CELL PRESS
- Keywords
- BH3-ONLY PROTEINS; BH3 DOMAINS; IN-VIVO; APOPTOSIS; REGULATORS; ACTIVATION; COMPLEX; FAMILY; DEATH
- Publisher's Version
- https://doi.org/10.1016/j.ccr.2005.06.012
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2005-07-01 12:00:00